Evaluating biologic agents in rheumatoid arthritis: a framework for clinical trials
Strand, V.; Scott, D.L.; Panayi, G.S.
Journal of Rheumatology 21(8): 1390-1392
1994
ISSN/ISBN: 0315-162X PMID: 7983635 Document Number: 433050
Document emailed within 1 workday
Related Documents
Valesini, G.; Montecucco, C.; Cutolo, M. 2006: Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy Clinical and Experimental Rheumatology 24(4): 413-423Baldini, C.; Delle Sedie, A.; Bombardieri, S. 2005: From clinical trials to the bedside: how can we treat patients with rheumatoid arthritis and concurrent morbidities who are generally excluded from randomised controlled clinical trials? Clinical and Experimental Rheumatology 23(6): 893-904
Yazici, Y.; McMorris, B.J.; Darkow, T.; Rosenblatt, L.C. 2009: Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis Clinical and Experimental Rheumatology 27(6): 907-913
Bellamy, N.; Anastassiades, T.P.; Buchanan, W.W.; Davis, P.; Lee, P.; McCain, G.A.; Wells, G.A.; Campbell, J. 1991: Rheumatoid arthritis antirheumatic drug trials. II. Tables for calculating sample size for clinical trials of antirheumatic drugs Journal of Rheumatology 18(12): 1901-1907
Kondo, H. 1997: Disease activity measures for rheumatoid arthritis clinical trials Ryumachi 37(6): 825-831
Koehn, C.L. 2005: The role of ethnicity in willingness to participate in rheumatoid arthritis clinical trials Journal of Rheumatology 32(12): 2283-2284
Lee, S.J.; Lenert, L.; Weisman, S.; Kavanaugh, A. 2005: Factors affecting rheumatoid arthritis patients' decisions to participate in clinical trials Journal of Rheumatology 32(12): 2317-2325
Pham, B.; Cranney, A.; Boers, M.; Verhoeven, A.C.; Wells, G.; Tugwell, P. 1999: Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials Journal of Rheumatology 26(3): 712-716
van der Heide, A.; Jacobs, J.W.; Schenk, Y.; Bijlsma, J.W. 1994: Endpoint measures in rheumatoid arthritis clinical trials: group summary and individual patient analysis Journal of Rheumatology 21(12): 2195-2199
Mäkinen, H.; Hannonen, P.; Sokka, T. 2006: Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission Clinical and Experimental Rheumatology 24(6 Suppl 43: S
Strand, V. 2004: Longer term benefits of treating rheumatoid arthritis: assessment of radiographic damage and physical function in clinical trials Clinical and Experimental Rheumatology 22(5 Suppl 35: S57-S64
Dancey, J.E.; Schoenfeldt, M. 2003: Clinical trials referral resource. Current clinical trials of agents targeting epidermal growth factor receptor Oncology 17(6): 819; 826
Feuchtenberger, M.; Kleinert, S.; Scharbatke, E.-C.; Gnann, H.; Behrens, F.; Wittig, B.M.; Greger, G.; Tony, H.-P. 2015: The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis Clinical and Experimental Rheumatology 33(3): 321-329
Henderson Berg, M.-H.; Carrasco, D. 2017: Injection Site Reactions to Biologic Agents Used in Psoriasis and Psoriatic Arthritis Journal of Drugs in Dermatology: Jdd 16(7): 695-698
Pincus, T.; Chung, C.; Segurado, O.G.; Amara, I.; Koch, G.G. 2006: An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis Journal of Rheumatology 33(11): 2146-2152
Aaltonen, K.J.; Turunen, J.H.; Sokka, T.; Puolakka, K.; Valleala, H. 2016: A survey on the medication adherence to methotrexate among rheumatoid arthritis patients treated with self-administered biologic drugs Clinical and Experimental Rheumatology 34(4): 694-697
Wolfe, F.; O'Dell, J.R.; Kavanaugh, A.; Wilske, K.; Pincus, T. 2001: Evaluating severity and status in rheumatoid arthritis Journal of Rheumatology 28(6): 1453-1462
Goodwin, J.S.; Ceuppens, J.L.; Rodriguez, M.A. 1983: Administration of nonsteroidal anti-inflammatory agents in patients with rheumatoid arthritis. Effects on indexes of cellular immune status and serum rheumatoid factor levels JAMA 250(18): 2485-2488
Wolfe, F.; Rehman, Q.; Lane, N.E.; Kremer, J. 2001: Starting a disease modifying antirheumatic drug or a biologic agent in rheumatoid arthritis: standards of practice for RA treatment Journal of Rheumatology 28(7): 1704-1711
Csepregi, A.; Nemesanszky, E.; Rojkovich, B.; Poor, G. 2001: Rheumatoid arthritis and hepatitis B virus: evaluating the pathogenic link Journal of Rheumatology 28(3): 474-477